Dr. Biwei Yang 杨毕伟
Chief Physician
Department of Medical Oncology (Liver Tumors), Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis of liver masses; non-surgical treatment of liver cancer including interventional procedures, ablation, targeted and immunotherapy. Specializes in transradial access interventions and managing refractory or elderly cases.
Graduated from Fudan University Shanghai Medical College in 1998 and joined Zhongshan Hospital. Currently an Associate Chief Physician at the Liver Cancer Institute and Department of Medical Oncology. Published 15 international papers, including one in Nature Communications, and received a National Natural Science Foundation grant.
Name order: in Chinese the family name comes first (Yang Biwei). Papers usually list the name as Biwei Yang or Yang B.
Selected publications
44 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2025 (senior author): SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma. PubMed 41316300
- J Med Case Rep, 2024 (senior author): Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report. PubMed 39709515
- J Gene Med, 2024 (senior author): Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its in-deep analysis in the liver cancer microenvironment: Evidence from large populations cohort. PubMed 37849429
- J Mol Recognit, 2019 (senior author): Molecular design and optimization of hepatic cancer SLP76-derived PLCγ1 SH3-binding peptide with the systematic N-substitution of peptide PXXP motif. PubMed 31397025
- Hepatol Res, 2019 (senior author): Oncogenic role of phospholipase C-γ1 in progression of hepatocellular carcinoma. PubMed 30623526
- Cell Prolif, 2019 (senior author): LncRNA NEAT1 promotes the tumorigenesis of colorectal cancer by sponging miR-193a-3p. PubMed 30407674
- Nat Commun, 2018 (first author): Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. PubMed 29445139
- Eur J Radiol, 2011 (first author): Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. PubMed 20303686
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion